Neuren Pharmaceuticals Limited (ASX: NEU)

Market Cap	1.75B
Revenue (ttm)	193.34M
Net Income (ttm)	117.29M
Shares Out	127.82M
EPS (ttm)	0.89
PE Ratio	15.31
Forward PE	17.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,147,833
Open	13.58
Previous Close	13.69
Day's Range	12.42 - 13.68
52-Week Range	12.02 - 25.95
Beta	2.13
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2023, Neuren Pharmaceuticals's revenue was 231.94 million, an increase of 1404.46% compared to the previous year's 15.42 million. Earnings were 157.08 million, an increase of 85270.11%.